List of Artificial Intelligence Companies in Canada - 45

Ability Biologics is dedicated to developing innovative, targeted, immune modulating biotherapeutics to address unmet medical needs in patients with cancer and autoimmune diseases. The company utilizes its powerful AbiLeap™ discovery engine, which combines massively parallel, continuously learning AI with advanced cell targeting technology, to develop the most potent and selective antibody therapeutics for areas of great unmet need.

Amplitude Ventures is a capital catalyst for highly innovative companies at the point of value acceleration. We work with Canada's most promising healthcare companies that share our vision of bringing groundbreaking technologies to patients. Amplitude is focused on building world-class Canadian companies in precision medicine and next-generation medical devices. Since 2012, the Amplitude team has deployed a venture growth model used to build Canadian companies with world-class management teams and scale companies to breakout potential. This model has been used by the team to create, build, and grow companies, resulting in over $1 billion in company value. Our offices are in Montreal, Toronto, and Vancouver.

We use next-gen machine learning to find novel psychedelic drug compounds. Classical (first-generation) psychedelics have never been optimized to treat any disease and so we aim to design compounds with the optimal risk-benefit ratio in various indications. Beyond mental health, we focus on neurodegeneration and neural injuries, increasing brain longevity and extending human mental healthspan.

Cancer doesn’t wait — so we shouldn’t either. At Avitia, we’re making sure that clinical labs and oncologists everywhere have the tools they need to diagnose, as well as treat cancer faster. Our AI/ML technology ensures partners have cost-effective NGS-based molecular testing solutions that provide rapid turnaround times. Now, we empower healthcare teams to skip the delays and focus on what matters — personalized patient care. From pinpointing cancer mutations to streamlining clinical trial access, we’re here to make precision oncology accessible for every community and improve patients’ quality of life. Let’s transform cancer care together. Le cancer n’attend pas, et nous ne devrions pas non plus attendre. Chez Avitia, nous veillons à ce que les laboratoires cliniques et les oncologues du monde entier disposent des outils dont ils ont besoin pour diagnostiquer et traiter le cancer plus rapidement. Notre technologie IA/ML garantit à nos partenaires des solutions de tests moléculaires NGS rentables qui offrent des délais d’exécution rapides. Désormais, nous permettons aux équipes de soins de santé d’éviter les retards et de se concentrer sur ce qui compte : des soins personnalisés aux patients. De l’identification des mutations cancéreuses à la rationalisation de l’accès aux essais cliniques, nous sommes là pour rendre l’oncologie de précision accessible à toutes les communautés et améliorer la qualité de vie des patients. Transformons ensemble les soins contre le cancer.

BenchSci is a biotechnology company that offers an AI-powered platform to accelerate biomedical research by providing researchers with antibody search and selection tools.

BioMark is an oncology-focused company with advanced near-to- market diagnostic technologies designed to improve patient outcomes. We have developed and own multiple intellectual properties (IPs) in detection and quantitation of metabolites. We hand-picked a proven, global enterprise team of scientists, engineers and medical professionals to help commercialize our innovative technology and to increase prediction and accuracy in the diagnosis of cancers by following and incorporating the highest regulatory ,clinical and scientific standards.. Our cross pollinated, balanced and committed team was established in 2007. Our mission is to develop and commercialize innovative technologies to increase prediction and accuracy in diagnosis of cancers.

BioVaxys Technology Corp. (CSE:BIOV, OTCQB:BVAXF, FR:5LB), formerly BioVaxys LLC, is a British Columbia-registered clinical-stage biotechnology company dedicated to improving patient lives with novel immunotherapies based on our DPX™ immune-educating delivery technology platform and our HapTenix© neoantigen tumor cell construct platform, for treating cancers, infectious disease, antigen desensitization, and other immunological fields. The Company’s clinical stage pipeline includes maveropepimut-S which is in Phase IIb clinical development for advanced Relapsed-Refractory Diffuse Large B Cell Lymphoma (DLBCL) and platinum resistant ovarian cancer, and BVX-0918, a personalized immunotherapeutic vaccine using our proprietary HapTenix© neoantigen tumor cell construct platform which is soon to enter Phase I in Spain for treating refractive late-stage ovarian cancer. BioVaxys is capitalizing on its tumor immunology know-how and creation of a unique library of T-lymphocytes & other datasets post-vaccination with its personalized immunotherapeutic vaccines to utilize predictive algorithms and other technologies to identify new targetable tumor antigens.

Smart, scalable, and automated insect farming. Bug Mars uses computer vision and machine learning to increase yield and profitability of insect farms for food, feed, and organic waste reduction.

Compugen is a clinical-stage therapeutic discovery and development company utilizing its broadly applicable predictive computational discovery capabilities to identify new drug targets and biological pathways for developing cancer immunotherapies. Compugen has developed two proprietary product candidates: COM701, a potential first-in-class anti-PVRIG antibody and COM902, a potential best-in-class antibody targeting TIGIT for the treatment of solid tumors. Compugen also has a clinical stage partnered program, rilvegostomig (previously AZD2936), a PD-1/TIGIT bispecific antibody where the TIGIT component is derived from Compugen’s clinical stage anti-TIGIT antibody, COM902, in Phase 3 development by AstraZeneca through a license agreement for the development of bispecific and multispecific antibodies. In addition, the Company’s therapeutic pipeline of early-stage immuno-oncology programs consists of programs aiming to address various mechanisms of immune resistance, of which the most advanced program, COM503, is in IND enabling studies is licenced to Gilead. COM503 is a potential first-in-class, high affinity antibody which blocks the interaction between IL-18 binding protein and IL-18, thereby freeing natural IL-18 in the tumor microenvironment to inhibit cancer growth. Compugen is headquartered in Israel, with offices in San Francisco, CA. Compugen’s shares are listed on Nasdaq and the Tel Aviv Stock Exchange under the ticker symbol CGEN.

CorVista Health is transforming cardiovascular care with the CorVista System, a non-invasive point-of-care diagnostic technology, that shortens the path from symptoms to diagnosis, empowering earlier treatment and better patient outcomes. The CorVista System leverages proprietary machine-learned algorithms and robust clinical data to deliver results providers can trust. For more information visit www.corvista.com

Deep Genomics is using artificial intelligence to build a new universe of life-saving genetic therapies. The future of medicine will rely on artificial intelligence, because biology is too complex for humans to understand. At Deep Genomics, our geneticists, molecular biologists and chemists develop new ways of detecting and treating disease using our biologically accurate artificial intelligence technology.

Entos Pharmaceuticals Inc. is a clinical-stage genetic medicines company. A new reality in genetic medicine lies ahead, one that will be ushered in with the advent of safe, effective, and redosable nucleic acid delivery technologies. At Entos, we develop next generation genetic medicines using our proprietary Fusogenix proteolipid vehicle (PLV) drug delivery system. Fusogenix PLVs are formulated with FAST proteins to enable the delivery of nucleic acid into target cells through direct fusion.

At Eyam, our mission is to bring “Next Generation” vaccine and therapeutic technologies to market to solve today's health care needs.

Geneseeq is a research-driven company providing cutting-edge next-generation sequencing (NGS) technology to accelerate precision cancer care. We offer both pan-cancer panels analyzing 400+ genes and cancer-type-specific gene panels for all sample types to help match a patient to the optimal treatment, including targeted therapy and immunotherapy for solid tumors and blood cancers. Additionally, we develop cutting-edge technologies and kits for minimal residual disease (MRD) monitoring and multi-cancer early detection (MCED). Our testing services are conducted in our CAP/CLIA/ISO15189-accredited laboratory, where we manufacture IVD and RUO testing kits for in-house solutions. With a global reach, our headquarters are located in both Canada and China. Our products and services are well-established and ordered by over 8,000 long-term oncologist partners across 12+ countries and regions. We are engaged in 2,200+ research projects with biopharma and research partners, providing high-quality genomic data to accelerate translational research. We work closely with our partners to address their specific needs, maintaining a relentless focus on quality and efficiency.

Based on world-leading technology, we are developing a unique ultrasound helmet that is as portable as it is precise. Our first disease target: Alzheimer’s disease.

IFOWONCO uses advanced computational modelling techniques coupled with state of the art machine learning to rapidly identify and optimize drug candidates.

Innodem Neurosciences is committed to improving the effectiveness and quality of life and care of patients with neurological problems. Innodem works with the pharmaceutical industry, leading medical professionals, and artificial intelligence experts to develop and promote Eye Movement Biomarkers (EMBs) & Gaze Mapping Biomarkers (GMBs) as important clinical assessment tools in the field of neurology. It is building a series of disease-specific tests embodied in an intuitive App that captures EMB & GMB data. The vision is that over time, while leveraging the latest advances in machine and deep learning, this EMB/GMB platform will assist users to accurately diagnose and monitor neurological disorders affecting eye-movements or cognition such as multiple sclerosis, Alzheirmer's, Parkinson's or related disorders, Frontotemporal dementia, Cancer-related cognitive impairment (Chemo Brain) and many others.

Insight Medbotics is developing MRI-guided robotics to bring together the insights only MRI can provide with the minimally invasive access and precision of robotics. Our MRI-compatible robot, IGAR, has been clinically demonstrated. As the only company to receive a FDA 510(k) clearance for use of a robot inside an MRI, Insight Medbotics is now advancing the technology to improve the standard of care for prostate cancer. Our vision is to bring our advanced MRI-guided robotic technology to procedures where accuracy and precision matter most to patients, physicians and hospitals.

Improving healthcare through innovative technology is at the core of Intelerad’s work. Our scalable medical imaging platform connects clinicians to a powerful imaging ecosystem that is fast, smart and tapped into the data they need, no matter their location. We’re focused on delivering a best-in-class medical image management solution that improves provider efficiency, decreases the cost of healthcare, and improves the overall health of populations. For more information, visit www.intelerad.com. L'amélioration des soins de santé grâce à des technologies innovantes est au cœur du travail d’Intelerad. Notre plateforme d'imagerie médicale évolutive connecte les cliniciens à un écosystème d’images puissant, rapide et intelligent qui exploite les données dont ils ont besoin, peu importe leur emplacement. Nous concentrons nos efforts pour offrir la meilleure solution de gestion d'images médicales de l’industrie, qui augmente l'efficacité des fournisseurs, qui réduit le coût des soins de santé et qui améliore la santé globale des populations. Pour plus d'information, visitez www.intelerad.com/fr.

Kapoose Creek Bio is a Canadian biotech company using AI technologies to uncover small molecule medicines from nature with unprecedented speed and scale. Our R&D efforts are supported by off-grid research facilities in the hunt for undiscovered chemistry in environments of unique biodiversity. We have developed a platform – unEarth Rx – that integrates phenotypic screening with advanced machine and deep learning to accelerate the identification of high-quality drug leads and simultaneously determine their mechanism of action. The result is a comprehensive, data-rich, functional map of nature's chemistry for accelerated discovery and development of new small molecule medicines. We are building a diversified portfolio of stakes in the next generation of critical medicines, focusing our platform on neuroscience, cancer and infectious disease. Currently our development pipeline is concentrated on lead assets with exciting potential in neurological indications.

Kingston Health Sciences Centre is a healthcare provider that offers a range of medical services and healthcare solutions.

KisoJi is dedicated to developing multi-specific antibody technologies and therapeutics that improve outcomes in oncology.

Life Chemicals Inc. Niagara-on-the-Lake, Canada, specializes in state-of-the-art organic synthesis for high-throughput screening: - Drug-like and lead-like screening compounds; - Carefully designed targeted libraries; - Building blocks and intermediates; - Custom synthesis projects. As an advanced synthetic laboratory Life Chemicals employs the high skills and research abilities of more than 80 qualified professionals. It also takes advantage of its co-operation with 14 leading Universities, Academic and industrial laboratories and is the largest exporter of their HTS compounds. Life Chemicals operates worldwide and in addition to its main office in Niagara-on-the-Lake, Canada, it has a US office in Orange, CT, and a European office in Munich, Germany. The production site is located in Kyiv, Ukraine. The Company sells its products and services to more than 1000 customers, with its sales volume steadily growing. Keeping pace with market demands, Life Chemicals does offer mutually beneficial terms and very competitive prices, thus making the ratio of product quality and its cost most attractive for our customers.

MYND Life Sciences Inc. is a leading life sciences company focused on improving mental health. The Company has confirmed access to Health Canada psilocybin research and development through licenses to its Chief Science Officer, Dr. Wilfred Jefferies. Patents have been filed based on historic research and development that commenced in 2016 regarding the modulation of a specific gene using neuro agents such as psychedelics and other compounds. Research and development is currently being performed.

Nanostics develops and commercializes novel, non-invasive diagnostic tests for cancer. Our core technology is an advanced liquid biopsy platform that can accurately diagnose cancer from a single drop of blood. Our lead product, ClarityDx Prostate, is the most accurate diagnostic test to diagnose aggressive prostate cancer. Go to https://www.nanosticsdx.com/clarity-dx-prostate/ to order ClarityDX Prostate today.

NetraMark combines proprietary QML/ML algorithms with cross-domain expertise to bring ML commercialization into reality, starting with the pharmaceutical space in drug development where we utilize large and small data in order to help pharmaceutical companies understand their patient populations better. Our technology allows for the utilization of phase II data in order to optimize phase III trials from the vantage of their specific patient population.

Noze is the global leader in digital odor perception (often hailed as the digital equivalent of the sense of smell). We have developed the world's most advanced digital nose, capable of detecting and identifying odors in real-world settings with unparalleled accuracy. Leveraging cutting-edge machine intelligence and a sensor developed with exclusively licensed NASA technology, Noze is committed to enhancing human health and wellbeing. Our mission is to improve patient outcomes by enabling real-time disease detection at any point-of-care by using our technology to target breath-based odor biomarkers.

OPTITHERA was founded in 2016 and has analyzed data from more than 20,000 type 2 diabetes patients from 20 countries. Based on these clinical studies and with the help of artificial intelligence, researchers were able to develop a genome test that can inform your physician if you are at risk of developing complications related to type 2 diabetes.

PanGenomic is a healthtech company on a mission to offer effective and accessible tools that transform the status quo in the world of mental and physical health. With a special focus on alternative and holistic care, brands like NARA, Mindleap, and MUJN are filling gaps left by conventional practices — and offering natural solutions that are safe, accessible, and backed by the latest science. By leveraging proprietary AI, and the latest tech, the PanGenomic family of products is poised to transform the experience of individuals, practitioners, teams, and the communities that surround them. PanGenomic Health is one of Canada's first public benefit corporations.

Pharma Inventor Inc. is a Canadian Chemistry R&D and Analytical Services company established to serve the needs of pharmaceutical, biotech and agrochemical industries as well as research institutes/academic research groups in North America to support their innovative R&D/Analytical testing activities. Reach out to us for Custom Organic Synthesis / Medicinal Chemistry / Analytical Services / Process Chemistry Works / IP Consultation.

Phenomic is an innovative biotech company based in Boston and Toronto that specializes in developing new medicines targeting the tumor stroma. The tumor stroma is a dense web of connective tissue that surrounds solid tumors and plays a crucial role in treatment resistance and disease progression. Phenomic's scTx platform contains an extensive and optimally-curated atlas of single-cell cancer and normal tissue data and is powered by proprietary machine learning software to provide unparalleled insight into target expression and selectivity. Using scTx, Phenomic can identify exquisitely selective targets that can directly reprogram the tumor microenvironment or deliver cancer-killing payloads such as immune engagers and antibody-drug conjugates. Additionally, Phenomic has developed tumor stroma-specific experimental systems, including co-culture and disease-relevant in vivo models, to dissect stromal biology and maximize the likelihood of clinical success. Phenomic's lead program targets a novel extracellular matrix protein identified by scTx that is highly tumor selective and expressed by a pathogenic subtype of cancer-associated fibroblasts we term ecmCAFs. We have demonstrated clear in vivo proof-of-concept for this program building our conviction in scTx’s ability to identify novel high-impact, druggable targets.

ProteinQure is a biotech company focused on the design of novel exotic peptides with broad therapeutic applications. Powered by atomic-level simulations and artificial intelligence, we design dynamic peptides that take drugs straight to their target – outperforming other treatment delivery systems. By daring to deliver therapeutics in a novel way we are changing the game for drug development and bringing hope to patients with previously untreatable diseases. At ProteinQure, we pride ourselves on our unique, diverse and cross-disciplinary team that brings together experts from experimental & computational biology, machine learning and software engineering.

PulseMedica has developed a proprietary real-time 3D imaging and laser targeting system for precise retinal surgery. Our patented next generation ultrafast femtosecond laser ophthalmic treatment will enable treatment for retinal diseases such as age-related macular degeneration (AMD) and glaucoma, for which there is currently no cure. PulseMedica is a company based out of Edmonton, AB, Canada.

Rakovina Therapeutics Inc. engages in the research and development of new cancer treatments based on a novel series of small-molecule DNA-damage response inhibitors. The company focuses on utilizing Deep Docking™ AI to target DNA-damage response (DDR) for oncology-focused treatments. Their target markets include breast cancer, ovarian cancer, and prostate cancer.

RetiSpec is an AI-based company focused on early detection of neurodegenerative diseases through a simple eye exam. RetiSpec's proprietary AI solution leverages existing retinal imaging cameras to provide a non-invasive, accurate and scalable solution for the early detection of Alzheimer's disease. RetiSpec is involved in multiple Alzheimer's and brain health studies in leading hospitals and research networks throughout North America. RetiSpec is currently advancing its regulatory and market entry plans for its first clinically-validated test to predict amyloid burden at the point of care, to aid in the evaluation of individuals for Alzheimer's disease and other causes of cognitive decline. RetiSpec was recently selected from more than 75 global applicants to receive the Davos Alzheimer's Collaborative inaugural grant for Health System Preparedness to test its technology in optometry settings.

Satisfai Health is on a mission to create the most comprehensive AI solution for gastrointestinal (GI) practice and research. To realize this vision, we aim to enhance the quality, speed, and affordability of existing methods for the detection, diagnosis, assessment and treatment of disease. Satisfai Health's AI products cover a range of applications in Upper and Lower GI, delivering innovative measurement, tracking and reporting on the most important clinical findings. Our core focus is enhancing human experiences. Through technology, we deliver personalized and precise approaches that benefit both caregivers and patients. Our solutions are used by pharmaceutical companies and contract research organizations in the drug development process, and will be used by practicing GI physicians in clinical practice. Our team is composed of highly experienced physicians, data scientists, software engineers and healthcare business professionals. We work with a network of globally recognized scientific and clinical experts, and are fortunate to be supported by some of the world's leading venture capital and private equity groups. We are growing quickly and always looking to add high quality talent in the right areas.

Scispot is the best tech stack for biotech. It's the first-ever toolkit that lets you tailor it to your needs – no coding required. Think of it as a super combo of alt-ELN + alt-LIMS + Integrations + Analytics. You can set it up using a user-friendly interface (GUI) or by entering commands (CLI). It's about making your digital biotech dreams a reality. You can design your data infrastructure, automate your workflows and integrations and make your data ready for machine learning and artificial intelligence – all on one spot. Scispot even provides pre-made blueprints for major experiments, teamwork, and data management. For product demo, book a call here: https://calendly.com/scispot/30min For investment opportunities, book a call here: https://calendly.com/scispot/scispot-intro-for-investors Scispot®

We address the inefficiency of clinical trial success that is currently at >90% failure rate. Simmunome is at the leading edge of leveraging AI towards unraveling biological complexity. We transform physiological systems into biologically representative computational models for use in therapeutic and preventative drug discovery. Despite the significant technological advances in biotechnology, high-throughput methods, and computational biology over the last 20 years, it has proven difficult to gain meaningful insights that translate into truly disruptive medicines. We combine fragmented data to create holistic models of disease that translate to helping you understand your drug's mechanism of action, increase efficacy in the right target population and predict your drug's safety profile. Ultimately getting you to market faster, reducing your R&D costs, and dramatically increasing your probability of success.

As Canada’s engaged university, SFU works with communities, organizations and partners to create, share and embrace knowledge that improves life and generates real change.

Sonic Incytes is committed to enhancing patient care through innovative diagnostic solutions. The company's flagship product, Velacur™, equips physicians with an advanced liver imaging tool to help manage the growing epidemic of fatty liver disease. Velacur offers real-time, AI guided quantification of the two key markers for fatty liver disease: liver stiffness and attenuation. With real-time results, a low up-front cost and AI guidance, VELACUR makes liver imaging at the point of care affordable and accessible.

Syantra Inc. is a precision healthcare company changing the way cancer is detected and treated, starting with breast cancer. Learn about Syantra DX | Breast Cancer. A blood test for breast cancer screening that's easy, convenient and accurate.

The University of Alberta is one of Canada's top teaching and research universities, with an international reputation for excellence across the humanities, sciences, creative arts, business, engineering, and health sciences. Home to more than 39,000 students and 15,000 faculty and staff, the university has an annual budget of $1.7 billion and attracts nearly $450 million in sponsored research revenue. The U of A offers close to 400 rigorous undergraduate, graduate, and professional programs in 18 faculties on five campuses. The university has more than 250,000 alumni worldwide. The university and its people remain dedicated to the promise made in 1908 by founding president Henry Marshall Tory that knowledge shall be used for "uplifting the whole people."​

Valence Labs is a biotechnology company that specializes in AI-driven drug discovery. It operates as a semi-autonomous research and productization engine within Recursion Pharmaceuticals. The company focuses on leveraging deep learning applications to enhance drug development, particularly for complex diseases. Valence Labs develops software tools that accelerate therapeutic research, including novel target identification and molecular design. In addition to its AI-driven initiatives, Valence Labs is associated with a separate entity that specializes in active pharmaceutical ingredient (API) synthesis. This division offers custom API manufacturing services, including process development and GMP-compliant commercial-scale production. Valence Labs collaborates with biotech partners to provide AI solutions, emphasizing complex chemistry and preclinical optimization.

Variational AI has developed Enki, the biopharma industry's first commercially-available foundation model for small molecules. Enki is based on a novel generative AI framework invented by Variational AI that has delivered novel and selective leads to multiple biopharma partners and customers.

Zilia is a health technology company developing a breakthrough platform to measure biomarkers in the eye, with an initial focus on ocular oximetry.